or Try an Advanced Search...

    Technical Analysis for INKT - MiNK Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.93 -0.01% 0.00
    INKT closed down 0.01 percent on Wednesday, May 8, 2024, on 17 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical INKT trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Doji - Bullish? Reversal 0.00%
    Down 3 Days in a Row Weakness 0.00%
    50 DMA Resistance Bearish -0.01%
    Fell Below 20 DMA Bearish -0.01%
    Fell Below 50 DMA Bearish -1.14%
    50 DMA Support Bullish -5.10%
    Crossed Above 20 DMA Bullish -5.10%
    Older End-of-Day Signals for INKT ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 11 hours ago
    60 Minute Opening Range Breakdown about 13 hours ago
    10 DMA Resistance about 13 hours ago
    Down 1% about 13 hours ago
    Rose Above 20 DMA about 14 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    INKT Chart by TradingView
    Basic chart:

    Profile

    MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Biology Immunology Pharmacy Stem Cell Cell Therapy T Cells Immune Mediated Diseases Natural Killer T Cell Lineage Cell Therapeutics

    Is INKT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 30 MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
    Apr 11 This MiNK Therapeutics Insider Increased Their Holding In The Last Year
    Apr 8 MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
    Mar 22 MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript
    Mar 22 Q4 2023 Mink Therapeutics Inc Earnings Call
    Mar 21 MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript
    Mar 21 MiNK Therapeutics GAAP EPS of -$0.16 misses by $0.01
    Mar 21 MiNK Reports Fourth Quarter and Year-End 2023 Results
    Feb 6 MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
    Jan 30 MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
    See more INKT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.34
    52 Week Low 0.75
    Average Volume 109,508
    200-Day Moving Average 1.12
    50-Day Moving Average 0.96
    20-Day Moving Average 0.93
    10-Day Moving Average 0.94
    Average True Range 0.08
    RSI (14) 47.64
    ADX 28.76
    +DI 25.60
    -DI 13.80
    Chandelier Exit (Long, 3 ATRs) 1.13
    Chandelier Exit (Short, 3 ATRs) 1.10
    Upper Bollinger Bands 1.02
    Lower Bollinger Band 0.84
    Percent B (%b) 0.51
    BandWidth 18.63
    MACD Line -0.01
    MACD Signal Line -0.01
    MACD Histogram 0.0014
    Fundamentals Value
    Market Cap 32.1 Million
    Num Shares 34.5 Million
    EPS -0.73
    Price-to-Earnings (P/E) Ratio -1.27
    Price-to-Sales 0.00
    Price-to-Book 10.05
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.98
    Resistance 3 (R3) 0.98 0.97 0.97
    Resistance 2 (R2) 0.97 0.95 0.96 0.97
    Resistance 1 (R1) 0.95 0.95 0.95 0.95 0.96
    Pivot Point 0.93 0.93 0.93 0.93 0.93
    Support 1 (S1) 0.92 0.92 0.91 0.91 0.90
    Support 2 (S2) 0.90 0.91 0.90 0.89
    Support 3 (S3) 0.88 0.90 0.89
    Support 4 (S4) 0.88